Accordingly, bisartans could have a dual role against COVID-19 by (1) preventing ANG II-induced toxic effects (pulmonary edema/inflammation/cytokine storm) and (2) blocking ACE2-spike protein interactions, particularly involving R and Zn active sites, thereby inhibiting cell entry of the virion. The gene discussed is AGT; the disease is COVID-19.